Skip to main content

Table 3 IRR of time to first AE stratified by diagnostic group. Poisson regression model, crude, and adjusted

From: Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

VariableRAPsAAS
Crude IRR (CI95%)pAdjusted IRR (CI95%)pCrude IRR (CI95%)pAdjusted IRR (CI95%)pCrude IRR (CI95%)pAdjusted IRR (CI95%)p
Age (ref. adults)*
 Young1.16 (0.62–2.17)0.6391.20 (0.62–2.33)0.5850.47 (0.19–1.13)0.0910.49 (0.18–1.31)0.1530.85 (0.52–1.39)0.531.13 (0.67–1.90)0.65
 Elderly1.59 (1.30–1.95)< 0.0011.55 (1.23–1.95)< 0.0011.60 (1.08–2.36)0.0191.25 (0.89–1.97)0.3361.36 (0.73–2.56)0.3361.34 (0.63–2.86)0.446
 Very Elderly1.77 (1.24–2.52)0.0021.76 (1.18–2.61)0.0054.35 (1.40–13.57)0.0114.40 (1.30–14.87)0.0175.94 (1.48–23.84)0.0122.86 (0.65–12.59)0.165
Women1.00 (0.83–1.20)0.991.14 (0.93–1.41)0.2091.72 (1.40–2.11)< 0.0011.60 (1.26–2.04)< 0.0011.35 (1.07–1.70)0.0121.42 (1.09–1.85)0.01
Treatments
 Corticosteroids1.01 (0.86–1.18)0.913  1.73 (1.37–2.18)< 0.0011.48 (1.13–1.93)0.0041.59 (1.17–2.16)0.0031.35 (0.95–1.91)0.098
 MTX1.26 (1.07–1.47)0.0041.25 (1.07–1.47)0.0061.34 (1.07–1.69)0.0121.31 (1.01–1.68)0.0411.78 (1.36–2.31)< 0.0011.56 (1.13–2.14)0.006
 Other1.08 (0.93–1.25)0.325  1.37 (1.09–1.72)0.0081.43 (1.09–1.88)0.011.02 (0.76–1.36)0.897  
Smoking (ref. No)
 Smoker/past smoker1.29 (1.09–1.53)0.0041.28 (1.05–1.57)0.0151.36 (1.07–1.73)0.0121.09 (0.81–1.46)0.5781.26 (1.01–1.58)0.0421.18 (0.90–1.54)0.234
Comorbidities
 Charlson Index1.12 (1.05–1.20)0.0011.08 (1.00–1.17)0.0481.13 (1.00–1.29)0.0561.09 (0.93–1.29)0.2931.26 (1.07–1.47)0.0051.28 (1.06–1.54)0.01
Time&1.00 (0.99–1.01)0.818  1.01 (0.99–1.03)0.399  1.01 (1.00–1.03)0.0081.02 (1.01–1.03)0.004
  1. *Age at the beginning of biological treatment
  2. &Time of disease duration
  3. AS ankylosing spondylitis, DMARDs disease-modifying antirheumatic drugs, IRR incidence rate ratio, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitor